Vyndaqel Remains Safe After 3 Years of Treatment, Analysis Shows
Vyndaqel (tafamidis meglumine) remains safe after more than three years of treatment in patients with familial amyloid polyneuropathy (FAP), with no new safety concerns raised, according to an early analysis of a clinical trial in Japan. The study, “Characteristics of Patients with Hereditary Transthyretin Amyloidosis…